CPHI — China Pharma Holdings, Inc.

Is CPHI overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Drug Manufacturers - Specialty & Generic

Strong Oversold As of August 19, 2026

China Pharma Holdings, Inc. (CPHI) currently reads Strong Oversold on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Drug Manufacturers - Specialty & Generic) last closed at $1.08. The rating moved from Oversold to Strong Oversold on August 19, 2026.

See all oversold Healthcare stocks →

AI analysis

Company exhibits typical small-cap China pharma characteristics: limited public disclosure and low liquidity create substantial information and market risk. Industry-level demand for biologics and outsourced manufacturing is a constructive thematic driver, but there are no clear, public near-term commercial catalysts or filings to validate revenue growth. Key considerations are the company’s undisclosed financial health, execution capacity to win CDMO/CRO or product contracts, and exposure to Chinese regulatory and geopolitical developments. Monitor for audited filings, partnership announcements, material contract wins, or management commentary that clarifies cash runway and revenue visibility before increasing exposure.

Key factors

  • Limited public financial disclosure and lack of recent EDGAR filings reduces visibility into balance sheet, cash runway and revenue trends
  • Small-cap / low-liquidity profile increases volatility and spreads; trading behavior can diverge from fundamentals
  • Exposure to China-based regulatory, manufacturing and supply-chain dynamics which can materially affect operations and margins
  • Sector tailwinds for biologics, CDMO/CRO services and specialty therapeutics create potential demand opportunities if the company participates in those markets
  • No clear near-term commercial catalysts publicly disclosed (no confirmed major partnerships, product launches, or material clinical readouts)
  • Macro environment is cautiously optimistic for risk assets but flows are favoring larger, higher-quality names — smaller issuers may see muted benefit

Risks

  • Sparse or delayed financial reporting could mask liquidity issues, related-party transactions or accounting concerns
  • Regulatory and policy risk in China, including changes to drug approval processes, pricing or cross-border trade controls
  • Execution risk: failure to secure commercial contracts, manufacturing scale agreements, or successful product launches
  • Market microstructure risk: low daily volume and high bid/ask spreads can amplify price moves and hamper exits
  • Currency and geopolitical risk (US-China tensions, sanctions, tariffs) that could disrupt supply chains or market access
  • Competitive pressure from larger, better-capitalized pharma and CDMO providers limiting margin expansion

See today's live rating, score and targets

Members see the live hourly rating for CPHI — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.